Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of valproic acid plus doxorubicin, cyclophosphamide, and vindesine in relapsed or refractory small cell lung cancer
2009-015105-39Phase 2Active
- Sponsor
- CHU de Lille
- Start
- Sep 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valproic acid, doxorubicin, cyclophosphamide and vindesine in small cell lung cancer (SCLC), sponsored by CHU de Lille. Primary endpoint: 6-month progression-free survival rate. Started Sep 2009; status: active.
02
Drugs
valproic aciddoxorubicincyclophosphamidevindesine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2009-015105-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015105-39.